OBJECTIVES: This study used a randomized withdrawal design to evaluate the efficacy of pregabalin versus placebo for pain relief in patients with painful diabetic peripheral neuropathy inadequately treated by other therapies. METHODS: A total of 665 patients receivedpregabalin in a 6-week single-blind phase. Two hundred ninety-four patients who achieved a ≥ 30% pain response were randomized to receive pregabalin or placebo in a double-blind phase for a further 13 weeks. The primary endpoint was the change in mean pain score from single-blind baseline to double-blind endpoint for pregabalin versus placebo (last observation carried forward [LOCF]). Secondary endpoints included a baseline observation carried forward (BOCF) analysis of mean pain score; time to loss of pain response; and other assessments of pain, sleep, function, and quality of life (QOL). RESULTS:Pregabalin numerically improved all measures assessed during the single-blind phase. At the end of the double-blind withdrawal phase, there was no significant difference in the primary endpoint of mean pain score (LOCF) between pregabalin and placebo (least squares mean difference, -0.32), although there was a significant difference in the BOCF analysis (least squares mean difference, -0.51). Pregabalin was associated with a significantly longer time to loss of pain response versus placebo during double-blind treatment, and some aspects of sleep and QOL also showed significant improvements with pregabalin. DISCUSSION: This is the first reported placebo-controlled trial of pregabalin in patients with inadequately treated painful diabetic peripheral neuropathy. Although the primary endpoint was not met, pregabalin was associated with clinically relevant improvements versus placebo in this difficult-to-treat population.
RCT Entities:
OBJECTIVES: This study used a randomized withdrawal design to evaluate the efficacy of pregabalin versus placebo for pain relief in patients with painful diabetic peripheral neuropathy inadequately treated by other therapies. METHODS: A total of 665 patients received pregabalin in a 6-week single-blind phase. Two hundred ninety-four patients who achieved a ≥ 30% pain response were randomized to receive pregabalin or placebo in a double-blind phase for a further 13 weeks. The primary endpoint was the change in mean pain score from single-blind baseline to double-blind endpoint for pregabalin versus placebo (last observation carried forward [LOCF]). Secondary endpoints included a baseline observation carried forward (BOCF) analysis of mean pain score; time to loss of pain response; and other assessments of pain, sleep, function, and quality of life (QOL). RESULTS: Pregabalin numerically improved all measures assessed during the single-blind phase. At the end of the double-blind withdrawal phase, there was no significant difference in the primary endpoint of mean pain score (LOCF) between pregabalin and placebo (least squares mean difference, -0.32), although there was a significant difference in the BOCF analysis (least squares mean difference, -0.51). Pregabalin was associated with a significantly longer time to loss of pain response versus placebo during double-blind treatment, and some aspects of sleep and QOL also showed significant improvements with pregabalin. DISCUSSION: This is the first reported placebo-controlled trial of pregabalin in patients with inadequately treated painful diabetic peripheral neuropathy. Although the primary endpoint was not met, pregabalin was associated with clinically relevant improvements versus placebo in this difficult-to-treat population.
Authors: Joe Alexander; Roger A Edwards; Marina Brodsky; Alberto Savoldelli; Luigi Manca; Roberto Grugni; Birol Emir; Ed Whalen; Steve Watt; Bruce Parsons Journal: Clin Drug Investig Date: 2019-08 Impact factor: 2.859
Authors: Sheena Derry; Rae Frances Bell; Sebastian Straube; Philip J Wiffen; Dominic Aldington; R Andrew Moore Journal: Cochrane Database Syst Rev Date: 2019-01-23
Authors: Dwight Moulin; Aline Boulanger; A J Clark; Hance Clarke; Thuan Dao; G A Finley; Andrea Furlan; Ian Gilron; Allan Gordon; Patricia K Morley-Forster; Barry J Sessle; Pamela Squire; Jennifer Stinson; Paul Taenzer; Ana Velly; Mark A Ware; Erica L Weinberg; Owen D Williamson Journal: Pain Res Manag Date: 2014 Nov-Dec Impact factor: 3.037
Authors: Joe Alexander; Roger A Edwards; Marina Brodsky; Luigi Manca; Roberto Grugni; Alberto Savoldelli; Gianluca Bonfanti; Birol Emir; Ed Whalen; Steve Watt; Bruce Parsons Journal: PLoS One Date: 2018-12-06 Impact factor: 3.240
Authors: Shazli Azmi; Kariem T ElHadd; Andrew Nelson; Adam Chapman; Frank L Bowling; Anughara Perumbalath; Jonathan Lim; Andrew Marshall; Rayaz A Malik; Uazman Alam Journal: Diabetes Ther Date: 2018-12-18 Impact factor: 2.945
Authors: Rainer Freynhagen; Michael Serpell; Birol Emir; Ed Whalen; Bruce Parsons; Andrew Clair; Mark Latymer Journal: Pain Pract Date: 2013-11-27 Impact factor: 3.183
Authors: Joe Alexander; Roger A Edwards; Alberto Savoldelli; Luigi Manca; Roberto Grugni; Birol Emir; Ed Whalen; Stephen Watt; Marina Brodsky; Bruce Parsons Journal: BMC Med Res Methodol Date: 2017-07-20 Impact factor: 4.615